Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous DNP-modified melanoma vaccine + cyclophosphamide + BCG
- Development stage
- Unknown
- Lead developer
- AVAX Technologies
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
A multi-component therapeutic cancer vaccine regimen composed of three elements: - **Autologous DNP-modified melanoma vaccine**: Tumor cells derived from the patient (autologous), chemically modified with the hapten dinitrophenyl (DNP) to enhance immunogenicity. - **Cyclophosphamide**: Low-dose chemotherapy administered as an immunomodulator to suppress regulatory T cells and potentiate the vaccine effect. - **BCG (Bacille Calmette–Guérin)**: A bacterial adjuvant, mixed with the vaccine to further stimulate local immune response. This regimen is used in the post-surgical (adjuvant) or metastatic melanoma setting. The vaccine’s mechanism involves stimulating delayed-type hypersensitivity (DTH) and activating T cell-mediated anti-tumor responses to melanoma antigens. Clinical studies suggest a correlation between robust DTH to unmodified melanoma cells and improved survival in melanoma patients. The regimen was primarily developed and clinically tested by academic centers and AVAX Technologies, but it has not received marketing approval due to regulatory and manufacturing challenges[1][2][3][4].
- Brand names
- MVAX
- Other names
- autologous dinitrophenyl-modified melanoma vaccine + cyclophosphamide + Bacille Calmette–Guérin
02
Targets
DNAPRR (Pattern recognition receptors)Dinitrophenyl-modified melanoma cell surface proteins
Beyond the preview
Go deeper on autologous DNP-modified melanoma vaccine + cyclophosphamide + BCG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous DNP-modified melanoma vaccine + cyclophosphamide + BCG.